We have demonstrated that there is a strong association between polymorphic poly-T variant of TOMM40 and the age of onset of late-onset Alzheimer's disease (AD). For APOE e3/4 patients who develop AD, those with long poly-T repeats linked to APOE e3 developed AD on average 7 years earlier than those with shorter poly-T polymorphisms linked to APOE e3. We have replicated this finding in a distinct population. In APOE e3/e3 homozygotes there is also a significant correlation between the length of the poly-T variant and grey matter density, which is independent of APOE e4. TOMM40 is in linkage disequilibrium with APOE and encodes the protein Translocase of the Outer Mitochondrial Membrane. Our central hypothesis is that the poly-T tract controls expression of TOMM40 and APOE in brain, and thus regulates the pathways in which these proteins participate. We will test this hypothesis at the genomic, genetic and biochemical levels. We will precisely identify the long, short and the ancestral poly-T tracts, and correlate the age o onset of AD and AD risk to these alleles. We will test our working model that the poly-T tract regulates TOMM40 and APOE expression by measuring APOE and TOMM40 mRNA and protein levels in rapidly autopsied human brain samples, and correlate these changes with susceptibility to AD-related damage across different brain regions. We will also construct two humanized mouse models of the TOMM40-APOE linkage disequilibrium region, that will permit more detailed, mechanism-based studies of the regulation of expression of these genes. We will exchange the mouse TOMM4-APOE linkage disequilibrium region with the homologous human region. Both models will be made homozygous for human APOE e3, thus eliminating possible confounding effects of APOE e4, and we will make one homozygous for the short poly-T polymorphism while we will make the other homozygous for the long poly-T variant. Successfully fulfilling these aims will advance our understanding of the molecular mechanisms underlying the genetic risk factors in AD and will provide valuable pathways for developing an effective preventive therapy for late-onset Alzheimer's disease.

Public Health Relevance

Alzheimer's disease is a critical unmet medical need. Currently more than five million Americans have AD and they cost Medicare $91 billion annually, and their caregivers provide billions in free care and cost their employers billions more in lost productivity. These trends will worsen because there are no disease-modifying therapies that improve dementia or the cognitive decline associated with it. Our studies build on a new genetics discovery to understand genetic factors affecting the rate of change in disease risk for AD with age that will lead to the discovery of preventive therapies for Alzheimer's disease.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project (R01)
Project #
Application #
Study Section
Molecular Neurogenetics Study Section (MNG)
Program Officer
Miller, Marilyn
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Chiba-Falek, Ornit; Gottschalk, William K; Lutz, Michael W (2018) The effects of the TOMM40 poly-T alleles on Alzheimer's disease phenotypes. Alzheimers Dement 14:692-698
Zeng, Yi; Nie, Chao; Min, Junxia et al. (2018) Sex Differences in Genetic Associations With Longevity. JAMA Netw Open 1:
Subramanian, Shobana; Gottschalk, William K; Kim, So Young et al. (2017) The effects of PPAR? on the regulation of the TOMM40-APOE-C1 genes cluster. Biochim Biophys Acta Mol Basis Dis 1863:810-816
Zeitlow, Kahli; Charlambous, Lefko; Ng, Isaac et al. (2017) The biological foundation of the genetic association of TOMM40 with late-onset Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis 1863:2973-2986
Chiba-Falek, Ornit; Lutz, Michael W (2017) Towards precision medicine in Alzheimer's disease: deciphering genetic data to establish informative biomarkers. Expert Rev Precis Med Drug Dev 2:47-55
Saul, Robert; Lutz, Michael W; Burns, Daniel K et al. (2016) The SSV Evaluation System: A Tool to Prioritize Short Structural Variants for Studies of Possible Regulatory and Causal Variants. Hum Mutat 37:877-83
Gottschalk, William K; Mihovilovic, Mirta; Roses, Allen D et al. (2016) The Role of Upregulated APOE in Alzheimer's Disease Etiology. J Alzheimers Dis Parkinsonism 6:
Lutz, Michael W; Sundseth, Scott S; Burns, Daniel K et al. (2016) A Genetics-based Biomarker Risk Algorithm for Predicting Risk of Alzheimer's Disease. Alzheimers Dement (N Y) 2:30-44
Gottschalk, William K; Lutz, Michael W; He, Yu Ting et al. (2014) The Broad Impact of TOM40 on Neurodegenerative Diseases in Aging. J Parkinsons Dis Alzheimers Dis 1:
Linnertz, Colton; Anderson, Lauren; Gottschalk, William et al. (2014) The cis-regulatory effect of an Alzheimer's disease-associated poly-T locus on expression of TOMM40 and apolipoprotein E genes. Alzheimers Dement 10:541-51